Free Trial

Climb Bio (NASDAQ:CLYM) Given "Sell (D-)" Rating at Weiss Ratings

Climb Bio logo with Medical background

Key Points

  • Climb Bio (NASDAQ:CLYM) received a "sell (D-)" rating from Weiss Ratings, despite some analysts upgrading it to a "hold" and others rating it as "strong-buy."
  • The company reported an earnings per share (EPS) of -$0.13, exceeding the consensus estimate of -$0.19, with expectations for the fiscal year EPS estimated at -$1.57.
  • Climb Bio's stock traded up 9.1% to $1.80 with a market capitalization of approximately $121.97 million, while having a 52-week price range between $1.05 and $5.47.
  • Interested in Climb Bio? Here are five stocks we like better.

Climb Bio (NASDAQ:CLYM - Get Free Report)'s stock had its "sell (d-)" rating reiterated by stock analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

CLYM has been the topic of a number of other reports. Wall Street Zen upgraded Climb Bio from a "sell" rating to a "hold" rating in a report on Monday. Baird R W raised Climb Bio to a "strong-buy" rating in a research report on Friday, August 15th. Robert W. Baird started coverage on Climb Bio in a research note on Friday, August 15th. They set an "outperform" rating and a $9.00 target price for the company. Finally, BTIG Research increased their price target on Climb Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday, September 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $9.25.

Get Our Latest Stock Report on CLYM

Climb Bio Trading Up 9.1%

Shares of Climb Bio stock traded up $0.15 on Wednesday, reaching $1.80. 593,481 shares of the company were exchanged, compared to its average volume of 543,366. Climb Bio has a fifty-two week low of $1.05 and a fifty-two week high of $5.47. The firm has a market capitalization of $121.97 million, a price-to-earnings ratio of -2.57 and a beta of -0.07. The stock has a fifty day moving average price of $2.06 and a 200-day moving average price of $1.55.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. On average, equities analysts anticipate that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Climb Bio

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in shares of Climb Bio during the 1st quarter worth $38,332,000. Affinity Asset Advisors LLC bought a new position in Climb Bio during the 1st quarter valued at about $1,830,000. Diadema Partners LP boosted its position in Climb Bio by 4.8% in the 2nd quarter. Diadema Partners LP now owns 702,135 shares of the company's stock valued at $871,000 after buying an additional 32,332 shares during the period. Peapod Lane Capital LLC purchased a new stake in shares of Climb Bio in the 1st quarter worth approximately $676,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in Climb Bio during the second quarter valued at approximately $575,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Climb Bio

(Get Free Report)

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.

See Also

Analyst Recommendations for Climb Bio (NASDAQ:CLYM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Climb Bio Right Now?

Before you consider Climb Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.

While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.